Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)-Reference-Cited by-同舟云学术

Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial)

Published:2002-09 Issue:6 Volume:90 Page:585-590
ISSN:0002-9149
Container-title:The American Journal of Cardiology
language:en
Short-container-title:The American Journal of Cardiology

Author:

Labinaz Marino,Madan Mina,O’Shea J.Conor,Kilaru Rakhi,Chin Wai,Pieper Karen,McGuire Darren K,Saucedo Jorge F,Talley J.David,Lui Henry,Kitt Michael M,Califf Robert M,Tcheng James E

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference18 articles.

1. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037–2044

2. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors;Lincoff;N Engl J Med,1999

3. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization;Topol;N Engl J Med,2001

4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade;Lancet,1998

5. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. The ESPRIT trial;O’Shea;JAMA,2001

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Abciximab in Diabetic Patients Who Underwent Percutaneous Coronary Intervention with Thienopyridines Loading: A Meta-Analysis;PLoS ONE;2011-06-03

2. The Impact of Diabetes Mellitus on Two-Year Mortality Following Contemporary Percutaneous Coronary Intervention: Implications for Revascularization Practice;Journal of Interventional Cardiology;2009-10

3. Tirofiban and Activated Protein C Synergistically Inhibit the Instant Blood Mediated Inflammatory Reaction (IBMIR) from Allogeneic Islet Cells Exposure to Human Blood;American Journal of Transplantation;2009-07

4. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment;Expert Review of Cardiovascular Therapy;2009-05

5. Re-evaluating risk factors for periprocedural complications during percutaneous coronary intervention in patients with unstable angina/non-ST-elevation myocardial infarction: who may benefit from more intensive antiplatelet therapy?;Current Opinion in Cardiology;2009-01